Mericana Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 14.76%
- Profit Growth 0.17%
- Ebitda 6.06%
- Net Worth 31.45%
- Total Assets 46.21%
About Mericana Pharmaceuticals
Mericana Pharmaceuticals Private Limited (MPPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 29 March 2019 (Five years and ten months 17 days old ). Its registered office is in Indore, Madhya Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Suresh Kshirsagar, Madan Sinha, Priyesh Sinha, and One other member serve as directors at the Company.
Company Details
-
Location
Indore, Madhya Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U33110MP2019PTC048220
-
Company No.
048220
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
29 Mar 2019
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at Mericana Pharmaceuticals?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suresh Kshirsagar
|
Director | 29-Mar-2019 | Current |
|
Madan Sinha
|
Director | 29-Mar-2019 | Current |
|
Priyesh Sinha
|
Director | 24-Sep-2020 | Current |
|
Gaurav Kshirsagar
|
Director | 24-Sep-2020 | Current |
Financial Performance of Mericana Pharmaceuticals.
Mericana Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 14.76% increase. The company also saw a slight improvement in profitability, with a 0.17% increase in profit. The company's net worth Soared by an impressive increase of 31.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mericana Pharmaceuticals?
In 2023, Mericana Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Welltek Lifesciences Private LimitedPriyesh Sinha and Gaurav Kshirsagar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Mericana Pharmaceuticals?
Unlock and access historical data on people associated with Mericana Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mericana Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mericana Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.